SGLT2 inhibitors in heart failure with reduced ejection fraction: a paradigm shift towards dual cardio-renal protection - Université de Lorraine Access content directly
Journal Articles Heart Failure Clinics Year : 2022

SGLT2 inhibitors in heart failure with reduced ejection fraction: a paradigm shift towards dual cardio-renal protection

Abstract

Sodium-glucose transport inhibitors (SGLT2i) have been found to be effective in preventing heart failure in patients with diabetes or chronic kidney disease with or without cardiovascular disease. Recent evidence suggests that SGLT2i substantially improve cardiovascular and renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF). In this review, we discuss the combined cardio-renal benefits of SGLT2i in patients with HFrEF. In addition, we discuss the impact of renoprotection in the midterm management of HFrEF and possible implementation strategies for initiating SGLT2i in routine care of HFrEF.
Fichier principal
Vignette du fichier
SGL2i in HFrEF_final.pdf (1.11 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03810997 , version 1 (11-10-2022)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

Tripti Rastogi, Nicolas Girerd. SGLT2 inhibitors in heart failure with reduced ejection fraction: a paradigm shift towards dual cardio-renal protection. Heart Failure Clinics, 2022, 18 (4), pp.561-577. ⟨10.1016/j.hfc.2022.03.006⟩. ⟨hal-03810997⟩
77 View
27 Download

Altmetric

Share

Gmail Facebook X LinkedIn More